Finally, we examined blood DCs in CLL patients undergoing BTK inhibitor (BTKi) acalabrutinib treatment and the relationship between DC deficiencies and clinical correlates. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.